IMMUNOSCAPE ANNOUNCES MEMORANDUM OF UNDERSTANDING FOR CLINICAL TRIAL WITH PREMIER U.S. CANCER CENTER

SINGAPORE & SAN DIEGO, March 5 (Bernama) -- ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the execution of a Memorandum of Understanding (MOU) with a premier NCI-designated Comprehensive Cancer Center in the United States, renowned globally for its pioneering history in cellular immunotherapy. This partnership will fast-track ImmunoScape's “Seed and Boost” platform into the clinic. Concurrently, the company announced a strategic investment from Leonardo DiCaprio.

Accelerating the “Seed and Boost” Clinical Program

Under the terms of the MOU, ImmunoScape will partner with the cancer center to launch an investigator-initiated clinical trial targeting Wilms Tumor 1 (WT1) positive solid tumors. The trial will focus on four difficult-to-treat indications: ovarian, mesothelioma, and other high-unmet need solid tumors such as pancreatic and colorectal cancers. The study is scheduled to dose its first patients by September 2026.